[Interaction of statins with clopidogrel].
Von Scheidt
W
W
I. Medizinische Klinik, Klinikum Augsburg. w.scheidt.med1@klinikum-augsburg.de
D015906:Angioplasty, Balloon, Coronary; D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001711:Biotransformation / Q000187:drug effects; D002423:Cause of Death; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D023903:Coronary Restenosis / Q000201:enzymology / Q000517:prevention & control*; D051544:Cytochrome P-450 CYP3A; D065607:Cytochrome P-450 Enzyme Inhibitors; D004347:Drug Interactions; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy / Q000201:enzymology / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011355:Prodrugs / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D012206:Rhabdomyolysis / Q000139:chemically induced*; D012307:Risk Factors; D015607:Stents; D020521:Stroke / Q000188:drug therapy / Q000201:enzymology / Q000401:mortality; D016019:Survival Analysis; D013988:Ticlopidine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D065607:Cytochrome P-450 Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D011355:Prodrugs; D000077144:Clopidogrel; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D013988:Ticlopidine